Drugs / NNC0581-0001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06891365 | Mar 2025 → Oct 2027 expected | fatty liver disease | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT05599945 | Nov 2022 → Aug 2025 | fatty liver disease | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0581-0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05599945 ↗ |
| Route | Subcutaneous | “single dose levels of subcutaneous NNC0581-0001 in a sequential manner” NCT05599945 ↗ |